TPG is said to be seeking over $3bn for the company, previously known as Axcan Pharma, which it acquired for $1.3bn in 2007.
Some potential buyers have baulked at the asking price and decided against making a formal bid, the report said.
TPG formed Aptalis in 2011 following the merger of Axcan Eurand Pharmaceuticals. The company develops and markets prescription products to treat gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, and cholestaticliver diseases. It recorded revenues of $615m and EBITDA of $269m for fiscal 2012, the report said.
TPG was recently reported to have asked for an additional year to invest its $19bn flagship fund TPG VI, which still has around $3bn of undeployed capital.
Copyright © 2013 AltAssets